FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes
E. de Poel, S. Spelier, M. C. Hagemeijer, P. van Mourik, S. W.F. Suen, A. M. Vonk, J. E. Brunsveld, G. N. Ithakisiou, E. Kruisselbrink, H. Oppelaar, G. Berkers, K. M. de Winter de Groot, S. Heida-Michel, S. R. Jans, H. van Panhuis, M. Bakker, R. van der Meer, J. Roukema, E. Dompeling, E. J.M. Weersink, G. H. Koppelman, A. R. Blaazer, J. E. Muijlwijk-Koezen, C. K. van der Ent, J. M. Beekman
Journal of Cystic Fibrosis, 2023, vol. 22, p.548-559
Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia
Gimano D Amatngalim, Lisa W Rodenburg, Bente L Aalbers, Henriette Hm Raeven, Ellen M Aarts, Dounia Sarhane, Sacha Spelier, Juliet W Lefferts, Iris Al Silva, Wilco Nijenhuis, Sacha Vrendenbarg, Evelien Kruisselbrink, Jesse E Brunsveld, Cornelis M van Drunen, Sabine Michel, Karin M de Winter-de Groot, Harry G Heijerman, Lukas C Kapitein, Magarida D Amaral, Cornelis K van der Ent, Jeffrey M Beekman
Life Science Alliance, 2022, vol. 5, p.1-14
Mutation-specific reporter for optimization and enrichment of prime editing
I F Schene, I P Joore, J H L Baijens, R Stevelink, G Kok, S Shehata, E F Ilcken, E E S Nieuwenhuis, D P Bolhuis, R C M van Rees, S A Spelier, H P J van der Doef, J M Beekman, R H J Houwen, E E S Nieuwenhuis, S A Fuchs
Nature Communications, 2022, vol. 13
